Apitope
Signal active
Organization
Contact Information
Overview
Apitope is a biotech company focused on the discovery and development of disease modifying therapies for autoimmune and allergic diseases, including multiple sclerosis, Graves’ disease, Factor VIII intolerance and uveitis. The company, whose first product candidate is licensed to Merck Serono, will now progress its remaining portfolio of product candidates developed with its proprietary platform technology.
About
Industries
Biotechnology, Health Care, Medical
Founded
2002
Employees
11-50
Headquarters locations
Europe
Social
N/A
Profile Resume
Apitope headquartered in Europe, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $952.0M in funding across 36 round(s). With a team of 11-50 employees, Apitope is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - Apitope, raised $13.5M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
3
Investors
5
Lead Investors
0
Total Funding Amount
$26.4M
Details
2
Apitope has raised a total of $26.4M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2008 | Early Stage Venture | 12.9M | ||
| 2015 | Early Stage Venture | 13.5M |
Investors
Apitope is funded by 10 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Apitope | - | FUNDING ROUND - Apitope | 13.5M |
| Arthurian Life Sciences | - | FUNDING ROUND - Arthurian Life Sciences | 13.5M |
| Apitope | - | FUNDING ROUND - Apitope | 13.5M |
| Limburgse Reconversie Maatschappij | - | FUNDING ROUND - Limburgse Reconversie Maatschappij | 13.5M |
Recent Activity
There is no recent news or activity for this profile.